The presence of an #antibody in serum/plasma is not a definitive indication of #immunity against #disease. HIV and HCV patients produce plenty of anti-HIV and anti-HCV antibodies, but these don't actually protect the host against coinfection with other genotypes/subtypes or disease. Same applies to #SarsCov2
The developer of an experimental immunotherapy delivering nanoscale payloads to treat pancreatic cancer says the treatment received fast-track status from the Food and Drug Administration.
A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.
The Department of Health and Human Services is allocating $100 million for venture investments in new technologies to prepare for future threats from Covid-19.
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study.
“Lectin fingerprinting can be used as a diagnostic tool for evaluating #antibody efficacy against #SARSCoV2 antigens and other glycosylated proteins. We anticipate that the method can be used to profile alterations in SARS-CoV-2 glycosylation that are present in rapidly emerging, highly infectious VOCs.”